Elevated serum receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in late-onset male hypogonadism

Clinical and Investigative Medicine

Volumn 34, Issue 4, 2011, Pages

  Pepene, Carmen E ^a   Crişan, Nicolae ^a   Coman, Ioan ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; FOLLITROPIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

AGED; ARTICLE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPOGONADISM; MALE; METABOLISM; ONSET AGE;

AGE OF ONSET; AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; FOLLICLE STIMULATING HORMONE; HUMANS; HYPOGONADISM; MALE; OSTEOPROTEGERIN; RANK LIGAND; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 80051827451     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappa B ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008;29:155-92.
2. Hofbauer LC, Hicok KC, Chen D, et al. Regulation of osteoprotegerin production by androgens and anti-androgens in hu man osteoblastic lineage cells. Eur J Endocrinol. 2002; 147:269-73.
3. Grundt A, Grafe IA, Liegibel U, et al. Direct effects of osteoprotegerin on human bone cell metabolism. Biochemical and Bio physical Research Communications. 2009;389:550-5.
4. Huber DM, Bendixen AC, Pathrose P, et al. Androgens suppress osteoclast formation induced by RANKL and macrophage colony stimulating factor. Endocrinology. 2001;142:3800-08.
5. Michael H, Härkönen PL, Väänänen HK, et al. Estrogen and testosterone use different cellular pathways to inhibit osteoclas togenesis and bone resorption. J Bone Miner Res. 2005;20:2224-32.
6. Kawano H, Sato T, Yamada T, et al. Suppressive function of an drogen receptor in bone resorption. Proc Nat Acad Sci USA. 2003;100: 9416-21.
7. Proell V, Xu H, Schüler C, et al. Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats. Bone. 2009;45:677-81.
8. Li X, Ominsky MS, Stolina M, Warmington KS, et al. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone, 2009;45: 669-76.
9. Khosla S, Atkinson EJ, Dunstan CR, et al. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab. 2002;87:1550-54.
10. Escobar-Morreale HF, Botella-Carretero JI, Martínez-García MA, et al. Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome. Eur J Endocrinol. 2008;159:225-32.
11. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, IS SAM, EAU, EAA and ASA recommendations. Eur J Endocri nol. 2008;159:507-14.
12. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666-72.
13. Vega D, Maalouf NM, Sakhaee K. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/ RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab. 2007;92:4514-21.
14. Franklin M, Bu SY, Lerner MR, et al. Dried plum prevents bone loss in a male osteoporosis model via IGF-I and the RANK pathway. Bone. 2006;39: 1331-42.
15. Gannagé-Yared MH, Fares F, Semaan M, Khalife S, Jambart S. Circulating osteoprotegerin is correlated with lipid profile, insu lin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol (Oxf). 2006;64: 652-58.
16. rd, et al. Correlates of osteo protegerin levels in women and men. Osteoporos Int. 2002; 13: 394-9.
17. Oh KW, Rhee EJ, Lee WY, et al. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associ ated with bone metabolism in middle-aged males. Clin Endo crinol (Oxf). 2005;62: 92-98.
18. Szulc P, Hofbauer LC, Heufelder AE, et al. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testos terone status. J Clin Endocrinol Metab. 2001;86: 3162-5.
19. Yeap BB, Almeida OP, Hyde Z, et al. In men older than 70 years, total testosterone remains stable while free testosterone declines with age. The Health in Men Study. Eur J Endocrinol. 2007;156:585-94.
20. Trofimov S, Pantsulaia I, Kobyliansky E, et al. Circulating levels of receptor activator of nuclear factor-kappa B ligand/osteoprotegerin/macrophage-colony stimulating factor in a pre sumably healthy human population. Eur J Endocrinol. 2004;150:305-11.
21. Fazzalari NL, Kuliwaba JS, Atkins GJ, et al. The ratio of messen ger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indi ces in normal human cancellous bone but not in osteoarthritis. J Bone Min Res. 2001;16:1015-27.
22. Siggelkow H, Eidner T, Lehmann G, et al. Cytokines, osteopro tegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. J Bone Min Res. 2003;18:529-38.
23. Hofbauer LC, Zeitz U, Schoppet M, et al. Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthr Rheum. 2009;60:1427-37.
24. Body JJ, Facon T, Coleman RE, Lipton, A, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res. 2006;15:1221-8.
25. Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab HALT Prostate Cancer Study Group. Denosumab in men re ceiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;20:745-755.
26. Jorgensen L, Vik A, Emaus N, Brox J, Hansen JB, Mathiesen E, Vestergaard P. Bone loss in relation to serum levels of osteopro tegerin and nuclear factor-kappaB ligand: the Tromsø Study. Osteoporos Int, 2010;21:931-8